Topics covered: Orphan Drug and Biologics Manufacturing, Oncology Drug Development, Genetic and Cell Therapies, FDA Approval Process, Cancer Immunotherapy, Biotechnology and Pharmaceuticals
Companies covered: Pfenex Inc. (AMEX:PFNX), Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Chimerix, Inc. (NASDAQ:CMRX), Assembly Biosciences, Inc. (NASDAQ:ASMB), Arrowhead Research Corporation (NASDAQ:ARWR), ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Pharmacyclics, Inc. (NASDAQ:PCYC), Merck & Company, Inc. (NYSE:MRK), Medivation, Inc. (NASDAQ:MDVN), Johnson & Johnson (NYSE:JNJ), Gilead Sciences, Inc. (NASDAQ:GILD), Dynavax Technologies Corporation (NASDAQ:DVAX), Dendreon Corp., Bristol-Myers Squibb Company (NYSE:BMY), Clovis Oncology, Inc. (NASDAQ:CLVS), Celgene Corporation (NASDAQ:CELG), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Pfizer, Inc. (NYSE:PFE), AstraZeneca PLC (NASDAQ:AZN), Allergan, Inc. (NYSE:AGN), bluebird bio, Inc. (NASDAQ:BLUE), WellPoint Inc., Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Novartis AG (NYSE:NVS), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Durect Corporation (NASDAQ:DRRX), NanoViricides, Inc. (NYSEAMERICAN:NNVC)
